North Carolina confirms no restoration of state-employee GLP-1 coverage

North Carolina's state budget, signed by Gov. Josh Stein in July 2026, does not restore weight-loss coverage for GLP-1 medications like Wegovy and Zepbound under the State Health Plan, which insures more than 750,000 teachers, state employees, retirees, and their dependents ^[1]. Meanwhile, NC Medicaid recorded more than $47.8 million in claims for weight-loss GLP-1s in June alone, covering 34,524 beneficiaries, or roughly 1.1% of the more than 3.1 million people covered by the program ^[1].

The two state programs have taken opposite paths since 2024. The State Health Plan Board of Trustees voted in January of that year to drop weight-loss GLP-1 coverage after more than 23,000 members were using the drugs at a net cost above $800 per member per month, with projected spending topping $170 million in 2024 and more than $1 billion over six years if coverage continued ^[1]. Four months later, Medicaid added coverage for FDA-approved obesity medications including Wegovy, Zepbound, and Saxenda, subject to prior authorization ^[1].

Medicaid's coverage briefly lapsed. Citing a funding shortage, NCDHHS ended obesity-only GLP-1 coverage on Oct. 1, 2025, while keeping coverage for diabetes and certain cardiovascular uses. Under a directive from Gov. Stein, the department restored the benefit effective Dec. 12, 2025 ^[1].

State Treasurer Brad Briner, who chairs the State Health Plan trustees, had pushed for a narrower benefit — about $100 million to cover an estimated 14,000 members with a body mass index of 38 or higher — but by May 2026 said he did not expect lawmakers to provide that funding. A Senate proposal in 2025 offered $25 million toward limited coverage, while the House proposed none ^[1]. The Plan has also struck an October 2025 deal with pharmacy benefit manager CVS Caremark allowing it to negotiate directly with manufacturers, but spokesperson Loretta Boniti said "current prices remain unaffordable given the Plan's financial condition" ^[1].

Why it matters for patients

For state employees, teachers, and retirees on the State Health Plan, the practical effect is unchanged access: weight-loss GLP-1s remain uncovered, though the Plan continues to cover the same drugs for members diagnosed with diabetes ^[1]. Boniti said the Plan "hopes to restore some level of coverage for GLP-1 medications for weight loss in the future," but called stabilizing its finances the immediate priority before expanding benefits ^[1].

For Medicaid beneficiaries, coverage currently continues, but the June claims data show average costs of about $1,386 per beneficiary before federal matching funds and manufacturer rebates are applied — figures NCDHHS says are significant but not publicly disclosed ^[1]. That financing structure, plus a track record of a three-month coverage lapse in late 2025, means Medicaid recipients face a different set of risks than State Health Plan members: continued access today, but exposure to future budget-driven cutoffs.

What happens next

Lawmakers have directed NCDHHS to develop a broader Medicaid cost-savings plan that would give managed care plans more flexibility to control GLP-1 use for weight loss, including mandatory participation in nutrition and lifestyle-management programs ^[1]. The department must submit that plan to the Joint Legislative Oversight Committee on Medicaid and the General Assembly's Fiscal Research Division by Oct. 1, 2026, though the law bars implementation before July 1, 2027 ^[1]. For the State Health Plan, no timeline has been set for when CVS Caremark negotiations might produce prices officials consider affordable enough to restore any weight-loss benefit ^[1].